发明名称 CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE
摘要 There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
申请公布号 US2014235606(A1) 申请公布日期 2014.08.21
申请号 US201414262863 申请日期 2014.04.28
申请人 AstraZeneca AB 发明人 Gullberg Britt Anne Ingela;Larsson Thomas Peter;Stonehouse Jeffrey Paul
分类号 C07D403/12;A61K45/06;A61K31/506 主分类号 C07D403/12
代理机构 代理人
主权项 1. A crystalline form of N-[2-[[(2,3-di:fluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide (also referred to as “Compound I”), characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 A, comprising at least one crystalline peak with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1.
地址 Sodertalje SE